Indication: Leukemia
Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: Stemline Therapeutics, Inc
Email for more information: Heme-NCIResearch@nortonhealthcare.org
